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Abstract Background: The oral multikinase inhibitor regorafenib improves overall survival
(OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments
have failed. This study investigated regorafenib plus modified FOLFOX (mFOLFOX6) as
first-line treatment of metastatic CRC.
Methods: In this single-arm, open-label, multicentre, phase II study, patients received
mFOLFOX6 on days 1 and 15, and regorafenib 160 mg orally once daily on days 4–10 and
18–24 of each 28-day cycle. The primary end-point was centrally assessed objective response
rate (ORR). Secondary end-points included disease control rate (DCR), OS, progression-free
survival (PFS) and safety.
Results: Median overall treatment duration with any study drug was 9.9 months (range
0.6–19.6); median treatment duration with regorafenib was 7.7 months (range 0.1–19.5); six
patients remained on regorafenib for more than 1 year. Fifty-three patients received at least
one dose of regorafenib. ORR was 43.9% (all partial responses); DCR was 85.4%; median
OS was not reached; median PFS was 8.5 months. Treatment-emergent adverse events were
experienced by all patients but were manageable with dose modifications.
Conclusion: Regorafenib + mFOLFOX6 as first-line treatment in patients with metastatic
CRC did not improve ORR over historical controls. Regorafenib plus mFOLFOX6 did not
appear to be associated with a markedly worse tolerability profile versus mFOLFOX6 alone.
ClinicalTrials.gov identifier: NCT01289821.
 2015 Published by Elsevier Ltd.
oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)
demonstrated an acceptable tolerability profile in
patients with metastatic CRC [7]. Pharmacokinetic data
revealed increased exposure to irinotecan, as well as its
active metabolite SN-38, when administered in
combination with regorafenib; however, regorafenib
did not significantly affect the pharmacokinetics of
either 5-FU or oxaliplatin [7]. The current study was
designed to assess the activity and tolerability of
regorafenib in combination with a modified FOLFOX
regimen (mFOLFOX6) as first-line therapy for meta-
static CRC.
2. Materials and methods
2.1. Study design and participants
The CORDIAL trial (ClinicalTrials.gov identifier:
NCT01289821) was an international, multicentre, sin-
gle-arm, open-label, phase II exploratory study con-
ducted at 16 centres in Australia, Belgium, Spain,
Germany, Italy, the United Kingdom (UK) and the
United States of America (USA) (investigators at each
site are listed in the Supplementary appendix). Ethical
approval of the study protocol was provided by each
centre’s institutional review board or independent ethics
committee. The trial followed the principles of the
Declaration of Helsinki and good clinical practice, com-
plying with all local laws and regulations. All patients
provided written informed consent before enrolment.
Patients had to be at least 18 years old, with
histological or cytological documentation of
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Every year, more than 1.36 million patients world-
wide are diagnosed with colorectal cancer (CRC) and
nearly 700,000 deaths are attributed to this disease [1].
At the time of diagnosis, up to 25% of patients present
with metastatic disease, while 50–60% of patients with
CRC will develop metastases at some point [2,3].
Standard treatment for these patients consists of a fluo-
ropyrimidine-based chemotherapy backbone combined
with other systemic cytotoxic agents, such as oxaliplatin
and irinotecan, together with monoclonal antibodies
such as bevacizumab and, in patients with RAS wild-
type tumours, cetuximab or panitumumab. These thera-
pies have improved overall survival (OS) from six to
around 20–24 months [2,4].
Regorafenib is an oral multikinase inhibitor that
blocks the activity of a variety of protein kinases
involved in the regulation of oncogenesis (KIT, RET,
RAF1, BRAF and BRAFV600E), angiogenesis (vascular
endothelial growth factor [VEGF] receptors 1–3 and
TIE2) and the tumour microenvironment (platelet-
derived growth factor receptor and fibroblast growth
factor receptor) [5]. The phase III CORRECT trial
demonstrated the efficacy and tolerability of regorafenib
monotherapy in patients with previously treated meta-
static CRC [6]. On the basis of those findings, regorafe-
nib monotherapy has been approved internationally for
patients with metastatic CRC previously treated with
other available standard therapies.
A phase I study of regorafenib in combination
with 5-fluorouracil (5-FU) + folinic acid with either
adenocarcinoma of the colon or rectum, and had to be
suitable to receive first-line treatment with
mFOLFOX6 for metastatic disease. Patients had to
have at least one measurable lesion according to
Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 [8], an Eastern Cooperative
Oncology Group performance status of 0 or 1, adequate
bone-marrow, liver and renal function and an antici-
pated life expectancy of at least 3 months. Exclusion
criteria included previous systemic anticancer therapy
for metastatic CRC (although adjuvant chemotherapy
for stages I–III CRC was permitted provided that ther-
apy had ceased >6 months before screening and disease
recurrence was documented), previous treatment with
anti-VEGF therapies or signal transduction inhibitors
or uncontrolled hypertension (systolic >150 mm/Hg or
diastolic >90 mm/Hg) despite optimal management.
Patient recruitment commenced in February 2011
and was stopped in July 2011 when the target number
of patients was reached. The data cut-off date for the
present analyses was 15th November 2012. The last
end-of-survival follow-up visit took place in June 2014.
2.2. Procedures
Patients were treated with a combination of
mFOLFOX6 plus regorafenib. The mFOLFOX6 regi-
men was administered according to normal clinical prac-
tice starting on days 1 and 15 of each 28-day cycle and
consisted of oxaliplatin 85 mg/m2 and folinic acid
400 mg/m2, both as 2-h intravenous (IV) infusions,
and 5-FU 400 mg/m2 as an IV bolus immediately fol-
lowed by a 2400 mg/m2 IV infusion over 46 h.
Regorafenib was given orally as a single morning dose
of 160 mg on days 4–10 and 18–24 of each 28-day cycle.
The treatment schedule is summarised in Fig. 1.
Treatment continued until death, tumour progression
(defined by RECIST), unacceptable toxicity, withdrawal
of consent or investigator’s decision to stop. If an
individual drug had to be withdrawn because of toxicity,
the patient could continue to receive the remaining com-
ponents until one of the above criteria was met. Dose
modifications were implemented for any individual com-
ponent of the combination therapy to manage toxicities
related to that drug. If patients stopped all components
of mFOLFOX6 and continued on single-agent regorafe-
nib, the treatment regimen for regorafenib was modified
to 160 mg once daily in repeating cycles of 3 weeks on/
1 week off treatment according to the schedule used
for regorafenib when given as monotherapy.
2.3. Study end-points
The primary end-point was objective response rate
(ORR) based on blinded central radiological review.
ORR was defined as the proportion of patients with a
best overall tumour response of partial or complete
response. Secondary end-points included disease control
rate (DCR; sum of complete response + partial
response + stable disease), progression-free survival
(PFS), OS, duration of response and duration of stable
disease. In addition, the safety and tolerability of the
regimen were evaluated using adverse events and
changes in laboratory measures (haematology, chem-
istry and urinalysis), vital signs (blood pressure, heart
rate and temperature) and electrocardiogram.
Although not a prespecified end-point, investigator-re-
ported duration of treatment was also assessed.
2.4. Assessments
Tumour assessment by CT or MRI was performed at
screening and every two cycles throughout the study
until disease progression was documented, using identi-
cal techniques at each assessment. Unless consent to fol-
low up was specifically withdrawn, survival assessments
were made every 2 months until death, via review of
medical records and regular contact. Safety was moni-
tored continuously until 30 ± 4 days after discontinua-
tion of treatment.
2.5. Statistical analysis
Statistical evaluation and estimation, using SAS ver-
sion 9.1 or higher (SAS Institute Inc., Cary, NC, USA),
were based on a one-sided type I error level of 10% and
a two-sided confidence level of 80%, respectively.
The primary end-point (ORR) was analysed based on
a one-sample exact binomial test. The aim was to assess
whether regorafenib plus mFOLFOX6 significantly
Fig. 1. Treatment schedule (28-day cycle). mFOLFOX6, modified regimen of folinic acid + 5-fluorouracil + oxaliplatin 6; od, once-daily.
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improved the ORR compared with that seen in a similar
population of historical cohorts. With a total planned
sample size of 41 evaluable patients in the primary
analysis set (i.e. all patients who were evaluated for
objective response), the null hypothesis was to be
rejected if at least 21 patients (51%) were classified as
responders. The estimated response rate and its two-
sided 80% confidence interval (CI) were given.
Variables measured on interval scales were sum-
marised using descriptive statistics, while frequency
tables were provided for variables measured on nominal
scales. Time-to-event data were displayed using Kaplan–
Meier estimates for survival functions.
3. Results
3.1. Patient demographics and characteristics
In total, 66 patients were screened for inclusion in
CORDIAL; 54 patients started the study and were
included in the full analysis set (FAS; Fig. 2). Patient
demographic and baseline tumour characteristics are
presented in Table 1.
At the time of data cut-off, five patients were still
receiving regorafenib treatment (regorafenib + 5-FU,
n = 2; regorafenib + 5-FU infusion only, n = 2; regora-
fenib monotherapy, n = 1). In November 2013, one
patient was still receiving regorafenib monotherapy.
Treatment duration and reasons for discontinuations
are summarised in Table 2.
3.2. Efficacy
In the primary analysis set (n = 41), a confirmed
ORR was observed in 43.9% of patients (n = 18; all par-
tial responses), while DCR (complete response + partial
response + stable disease) was observed in 85.4% of
patients (n = 35); no patients achieved a complete
response (Table 3). The findings were similar in the
per-protocol analysis (n = 48; see Table 3).
Kaplan–Meier estimates of OS and PFS in the FAS
are presented in Fig. 3. The median duration of clinical
Fig. 2. Flow of patients through the study.
Table 1
Patient demographic and baseline tumour characteristics (full analysis
set, N = 54).
Characteristic n %
Male:female ratio 28:26 51.9:48.1
Age (years)
Median (range) 61 (32–80) 61.1
<65 33 33.3
65–75 18 5.6
P75 3
ECOG performance status
0 35 64.8
1 19 35.2
Primary disease site
Colon 35 64.8
Rectum 15 27.8
Colon and rectum 4 7.4
TNM stage at diagnosis
I 1 1.9
IIa 5 9.3
IIIb/c 7 13.0
IV 41 75.9
Number of target lesions
0 2 3.7
1 3 5.6
2–3 42 77.8
4–5 7 13.0
ECOG, Eastern Cooperative Oncology Group; TNM, tumour, node,
metastasis.
Table 2
Treatment duration and reasons for discontinuation (full analysis set,
N = 54).
Any study
treatmenta
Regorafenibb
Treatment duration
Months (median [range]) 9.9 (0.6–19.6) 7.7 (0.1–19.5)
Cycles (median [range]) 8 (1–21) 7 (1–21)
Patients on treatment
>6 months (n [%])
26 (48.1) 29 (53.7)
Patients on treatment >1 year
(n [%])c
6 (11.1) 6 (11)
Reasons for treatment discontinuation (n [%])
Disease progression 39 (72.2)
Adverse events 4 (7.4)
Investigator’s decision 3 (5.6)
Patient withdrawal 1 (1.9)
a Regorafenib, oxaliplatin, folinic acid and/or 5-fluorouracil (5-FU).
b As combination therapy or monotherapy.
c Regorafenib + mFOLFOX6, n = 1; regorafenib + 5-FU, n = 2;
regorafenib + 5-FU infusion only, n = 2; regorafenib monotherapy,
n = 1.
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response in patients with an objective response (n = 20)
was 9.0 months (95% CI 6.6 months to not reached),
while the median duration of stable disease in patients
with stable disease as the best response (n = 22) was
7.6 months (95% CI 5.5–8.5 months). Change in target
lesion volume from baseline is shown in Fig. 4.
3.3. Safety
In total, 52 patients (98.1%) received greater than
90% of the planned regorafenib dose, with 51 patients
(96.2%) requiring regorafenib dose modifications
(reductions or interruptions) as a result of adverse
events (Table 4).
All 53 patients who received study medication experi-
enced at least one treatment-emergent adverse event
(TEAE) during the study. TEAEs affecting more than
20% of patients are presented in Table 5. No grade 5
TEAEs were reported. Serious TEAEs occurred in 21
patients (39.6%), with drug-related serious TEAEs
reported in 13 patients (24.5%). Overall, TEAEs led to
dose modifications in 51 patients (96.2%), with discon-
tinuation of a component of study treatment required
by 19 patients (35.8%) and discontinuation of full study
treatment in four patients (8%). The most frequent
Table 3
Centrally assessed response using RECIST version 1.1.
Primary analysis set (N = 41) Per-protocol set (N = 48)
n (%) 80% CI n (%) 80% CI
Best overall response Complete response 0 0.0–3.9 0 0.0–3.3
Partial response 18 (43.9) 33.2–55.1 20 (41.7) 31.9–52.0
Stable disease 17 (41.5) 30.9–52.7 22 (45.8) 35.9–56.1
Progressive disease 5 (12.2) 6.1–21.5 5 (10.4) 5.2–18.5
Missing 1 (2.4) 0.3–9.2 1 (2.1) 0.22–7.9
DCRa 35 (85.4) 75.7–92.1 42 (87.5) 79.1–93.3
ORRb 18 (43.9) 33.2–55.1 20 (41.7) 31.9–52.0
CI, confidence interval; DCR, disease control rate; ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors.
a DCR defined as complete response + partial response + stable disease (stable disease had to be maintained for P7 weeks).
b ORR defined as complete response + partial response.
Fig. 3. Kaplan–Meier estimates of (A) overall survival (median not
reached because >50% of patients were still alive at the cut-off date; 38
censored [70.4%]) and (B) progression-free survival (median
8.5 months, 95% confidence interval 7.4–11.3 months; median time to
treatment failure 7.8 months, 95% confidence interval 6.2–
11.2 months). Full analysis set, N = 54.
Fig. 4. Best change in target lesion size from baseline (full analysis set,
N = 54). Best change could not be determined in two patients. Six
patients (11.1%) had increases in tumour size, while 46 patients (85.2%)
had tumour shrinkage. Maximum tumour reductions of P30% were
recorded in 29 patients (53.7%).
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adverse events leading to regorafenib dose reductions
were diarrhoea and hand–foot skin reaction. The most
frequent adverse events leading to oxaliplatin dose
reduction were neurotoxicity, paraesthesia and diar-
rhoea, while the most frequent adverse events resulting
in 5-FU dose reduction were neutropenia, diarrhoea
and decreased platelets.
4. Discussion
The CORDIAL study failed to reach its primary end-
point, with the ORR in patients receiving regorafenib
and mFOLFOX6 showing little difference from that
seen with standard therapy alone. The combination of
regorafenib and mFOLFOX6 was associated with a
comparable median PFS (8.5 months) to FOLFOX
and FOLFIRI chemotherapy alone (8.0 and 8.5 months,
respectively) [9]. Median PFS in the current study
appeared to be longer than that in most trials investigat-
ing chemotherapy and kinase inhibitor combinations
(Supplementary Table 1) [10,11].
The apparent lack of improvement in tumour
shrinkage following the addition of regorafenib to
mFOLFOX6 versus historical data for chemotherapy
alone (ORR of 43.9% versus an expected 35–55% for
mFOLFOX6 alone [9,12–16]) together with the slowing
of tumour growth observed in CORDIAL (as suggested
by the higher than expected PFS) are consistent with
results from the phase III CORRECT trial [6]. In
CORRECT, regorafenib monotherapy significantly
increased OS and PFS compared with placebo, despite
a negligible ORR of 1.4% in a refractory population that
had received multiple prior lines of therapy. The obser-
vations from CORDIAL and CORRECT could support
a cytostatic rather than a cytotoxic effect of regorafenib
on metastatic CRC. It may be possible to determine
whether this theorised effect translates into prolonged
OS once data are available from longer-term follow up
of patients in CORDIAL.
The limitations of the CORDIAL study are its single-
arm design and relatively small population. Despite the
small sample size and exploratory nature of the trial, the
PFS and ORR results are consistent with those reported
with regimens containing other small-molecule kinase
inhibitors (such as cediranib, vatalanib and sunitinib),
while the duration of treatment in CORDIAL appears
to be prolonged compared with those agents
(Supplementary Table 1) [10,11,17].
The design of the CORDIAL study allowed modifica-
tion of any component of the study treatment to manage
adverse events. As a result of this tailored approach, the
study showed that this combination regimen had a man-
ageable tolerability profile in the first-line treatment of
patients with metastatic CRC. Overall, the adverse
event profile of the regorafenib plus mFOLFOX6
Table 4
Dose modifications (safety population, N = 53).
Regorafenib Oxaliplatin 5-FU bolus 5-FU infusion
Patients requiring dose interruptions or delays (n [%])
Any 50 (94.3) 48 (90.6) 46 (86.8) 47 (88.7)
1–3 27 (50.9) 21 (39.6) 19 (35.8) 18 (33.9)
>3 23 (43.4) 27 (50.9) 27 (50.9) 29 (54.7)
Patients requiring dose reductions (n [%])
Any 25 (47.2) 37 (69.8) 29 (54.7) 30 (56.6)
1 15 (28.3) 25 (47.2) 28 (52.8) 22 (41.5)
2 10 (18.9) 11 (20.8) 3 (5.7) 9 (17.0)
5-FU, 5-fluorouracil.
Table 5
Treatment-emergent adverse events occurring in P20% of patients (safety population, N = 53).
Adverse event (n [%]) Any grade Grade 1 Grade 2 Grade 3 Grade 4
Diarrhoea 37 (69.8) 16 (30.2) 9 (17.0) 12 (22.6) 0
Neutropenia 34 (64.2) 2 (3.8) 11 (20.8) 13 (24.5) 8 (15.1)
Fatigue 34 (64.2) 20 (37.7) 12 (22.6) 2 (3.8) 0
Hypertension 29 (54.7) 4 (7.4) 10 (18.9) 13 (24.5) 2 (3.8)
Paraesthesia 28 (52.8) 14 (26.4) 9 (17.0) 5 (9.4) 0
Abdominal pain 27 (50.9) 14 (26.4) 11 (20.8) 2 (3.8) 0
Nausea 26 (49.1) 23 (43.4) 2 (3.8) 1 (1.9) 0
Thrombocytopenia 25 (47.2) 10 (18.9) 11 (20.8) 4 (7.5) 0
Oral mucositis 24 (45.3) 15 (28.3) 8 (15.1) 1 (1.9) 0
Peripheral neuropathy 24 (45.3) 13 (24.5) 4 (7.5) 7 (13.2) 0
Anorexia 19 (35.8) 15 (28.3) 3 (5.7) 1 (1.9) 0
Hand–foot skin reaction 19 (35.8) 7 (13.2) 10 (18.9) 2 (3.8) 0
Constipation 16 (30.2) 13 (24.5) 2 (3.8) 1 (1.9) 0
Dysgeusia 16 (30.2) 14 (26.4) 2 (3.8) 0 0
Vomiting 16 (30.2) 12 (22.6) 2 (3.8) 2 (3.8) 0
Alopecia 15 (28.3) 13 (24.5) 2 (3.8) 0 0
Increased lipase 14 (26.4) 4 (7.5) 0 9 (17.0) 1 (1.9)
Anaemia 12 (22.6) 4 (7.5) 6 (11.3) 2 (3.8) 0
Voice alteration 12 (22.6) 11 (20.8) 1 (1.9) 0 0
Increased aspartate aminotransferase 12 (22.6) 8 (15.1) 1 (1.9) 3 (5.7) 0
Hypophosphataemia 11 (20.8) 0 4 (7.5) 7 (13.2) 0
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combination appeared to be generally consistent with
that of chemotherapy alone, although some regorafe-
nib-related TEAEs, such as hand–foot skin reaction,
were reported in addition to chemotherapy-related
TEAEs. Of note, discontinuation of all study treatment
(chemotherapy and regorafenib) as a result of TEAEs
only occurred in four patients, with most patients con-
tinuing at least one component of study treatment
[9,12–16].
In other studies of tyrosine kinase inhibitors in
combination with chemotherapy, a decreased dose
intensity of the chemotherapy components has been
implicated in the apparent lack of efficacy. In
CORDIAL, the intermittent dosing schedule could pos-
sibly underlie both the tolerability profile of regorafenib
in combination with chemotherapy and the apparent
antitumour activity, by avoiding any negative interac-
tion between the impact of regorafenib on cell replica-
tion and the efficacy of the chemotherapy components.
This hypothesis was first proposed in a serial imaging
study of the VEGF receptor inhibitor axitinib; that
study showed marked inhibition of fluorothymidine
uptake during continuous treatment for 7 days, suggest-
ing inhibition of cancer cell proliferation, which might
protect against the cytotoxic effects of chemotherapy.
The authors of that study hypothesised that this effect
could explain the failure of VEGF receptor inhibitors
in combination with chemotherapy regimens to improve
outcomes [18].
Although duration of treatment was not a prespeci-
fied end-point, it is interesting to note that six patients
received at least one component of study medication
for 1 year or longer, with an overall median treatment
duration for any component of study treatment of
9.9 months and five patients still receiving regorafenib
therapy more than 6 months after data cut-off (regorafe-
nib + 5-FU, n = 2; regorafenib + 5-FU infusion only,
n = 2; regorafenib monotherapy, n = 1). The relatively
long duration of treatment observed, albeit from a phase
II study, contrasts with data from phase III studies of
other first-line therapies for metastatic CRC, in which
the duration of treatment rarely exceeds 6 months
(Supplementary Table 2) [9,12–16].
The study did not meet its primary end-point, with no
increase in the response rate compared with historical
data from patients treated with mFOLFOX6 alone.
Thus, the combination of regorafenib and
mFOLFOX6 given in this schedule cannot be consid-
ered to be synergistic. However, given the median dura-
tion of treatment (9.9 months), together with some
patients receiving at least one component of study ther-
apy for more than 1 year, it would be interesting to
explore the hypothesis that the addition of regorafenib
to standard treatment might help patients to continue
on treatment, and thus maintain tumour control for
longer than might be achieved with chemotherapy alone.
Characterisation of patients who could derive the most
long-term benefit, and the impact of dose modifications
on tolerability and treatment duration, might provide
the groundwork for investigation of the use of regorafe-
nib as maintenance therapy in patients with metastatic
CRC who have achieved a clinical response to cytotoxic
chemotherapy.
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